TWI347947B - Process for preparing [4-(1,3,4-oxadiazol-2-yl)phenyl] boronic acid and use thereof - Google Patents

Process for preparing [4-(1,3,4-oxadiazol-2-yl)phenyl] boronic acid and use thereof

Info

Publication number
TWI347947B
TWI347947B TW094104918A TW94104918A TWI347947B TW I347947 B TWI347947 B TW I347947B TW 094104918 A TW094104918 A TW 094104918A TW 94104918 A TW94104918 A TW 94104918A TW I347947 B TWI347947 B TW I347947B
Authority
TW
Taiwan
Prior art keywords
oxadiazol
phenyl
preparing
boronic acid
boronic
Prior art date
Application number
TW094104918A
Other languages
English (en)
Other versions
TW200538451A (en
Inventor
Margaret Anne Butlin
Roger Butlin
Philip John Hogan
Andreas Meudt
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200538451A publication Critical patent/TW200538451A/zh
Application granted granted Critical
Publication of TWI347947B publication Critical patent/TWI347947B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
TW094104918A 2004-02-20 2005-02-18 Process for preparing [4-(1,3,4-oxadiazol-2-yl)phenyl] boronic acid and use thereof TWI347947B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0403744.6A GB0403744D0 (en) 2004-02-20 2004-02-20 Chemical process

Publications (2)

Publication Number Publication Date
TW200538451A TW200538451A (en) 2005-12-01
TWI347947B true TWI347947B (en) 2011-09-01

Family

ID=32040047

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094104918A TWI347947B (en) 2004-02-20 2005-02-18 Process for preparing [4-(1,3,4-oxadiazol-2-yl)phenyl] boronic acid and use thereof

Country Status (32)

Country Link
US (2) US7626020B2 (zh)
EP (3) EP1718655A2 (zh)
JP (2) JP2007523906A (zh)
KR (2) KR101196111B1 (zh)
CN (1) CN1922193B (zh)
AR (1) AR047810A1 (zh)
AT (1) ATE535532T1 (zh)
AU (1) AU2005214138B2 (zh)
BR (1) BRPI0507847A (zh)
CA (1) CA2555554A1 (zh)
CL (1) CL2011003138A1 (zh)
CY (1) CY1112555T1 (zh)
DK (1) DK2135873T3 (zh)
ES (1) ES2375201T3 (zh)
GB (1) GB0403744D0 (zh)
HK (1) HK1139689A1 (zh)
HR (1) HRP20120031T1 (zh)
IL (2) IL177505A (zh)
MY (1) MY142268A (zh)
NO (1) NO20064012L (zh)
PL (1) PL2135873T3 (zh)
PT (1) PT2135873E (zh)
RS (1) RS52300B (zh)
RU (1) RU2386636C2 (zh)
SA (1) SA05260017B1 (zh)
SG (1) SG153856A1 (zh)
SI (1) SI2135873T1 (zh)
TW (1) TWI347947B (zh)
UA (1) UA83418C2 (zh)
UY (1) UY28754A1 (zh)
WO (1) WO2005080403A2 (zh)
ZA (1) ZA200606579B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
CA2667545A1 (en) * 2006-10-25 2008-05-02 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
PE20091838A1 (es) * 2008-04-09 2009-12-18 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de acido graso
JP2012523425A (ja) 2009-04-07 2012-10-04 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼの阻害薬
CA2757679A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
RU2569061C2 (ru) 2010-02-03 2015-11-20 Инфинити Фармасьютикалз, Инк. Ингибиторы амид-гидролазы жирных кислот
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
CN108368543B (zh) 2015-10-12 2023-06-13 领先细胞医疗诊断有限公司 高噪声样品中原位检测核苷酸变体及相关的组合物和方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (zh) 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (zh) 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5965732A (en) 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
WO1996009818A1 (en) 1994-09-27 1996-04-04 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
GB2295616A (en) 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
GB9704762D0 (en) * 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
AU3011299A (en) 1998-03-23 1999-10-18 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
CA2330447C (en) 1998-04-29 2009-06-30 Pfizer Products Inc. N-(3-ethynylphenyl-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
ATE457169T1 (de) 1998-10-15 2010-02-15 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
DE19857765A1 (de) * 1998-12-15 2000-06-21 Clariant Gmbh Verfahren zur Herstellung von para-Oxadiazolyl-phenyl-boronsäuren
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
JP2003520785A (ja) 1999-12-15 2003-07-08 ブリストル−マイヤーズ スクイブ カンパニー アンジオテンシン・エンドセリン受容体二重拮抗薬としてのビフェニルスルホンアミド類
US6774131B1 (en) 2000-02-16 2004-08-10 Yamanouchi Pharmaceutical Co., Ltd. Remedies for endothelin-induced diseases
BR0111207A (pt) 2000-05-31 2003-04-01 Warner Lambert Co Combinações de um antagonista receptor de endotelina e um composto antiepiléptico tendo propriedades de alìvio da dor ou analgésicos
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
DE10113366A1 (de) 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2002049630A2 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
KR20100036390A (ko) 2001-03-06 2010-04-07 셀러지 파마세우티칼스, 인크 비뇨생식기 장애 치료용 화합물 및 그 방법
GB0108689D0 (en) 2001-04-05 2001-05-30 Medical Res Council Neuropathologies associated with expression of TNF-a
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
WO2002085351A1 (en) 2001-04-11 2002-10-31 Abbott Laboratories Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
WO2003006041A1 (fr) 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes
WO2003009805A2 (en) 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
JP2005504040A (ja) * 2001-08-03 2005-02-10 スミスクライン ビーチャム コーポレーション カテプシンK阻害剤としてのα−ケトアミド誘導体
EP1424080B1 (en) 2001-08-10 2011-02-16 Takeda Pharmaceutical Company Limited Gnrh agonist combination drugs
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223367D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
DK1761515T3 (da) 2003-12-20 2009-02-16 Merck Patent Gmbh 2-(hetero-)aryl-substituerede tetrahydroquinolinderivater
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) 2005-07-19 2005-08-24 Astrazeneca Ab Salt

Also Published As

Publication number Publication date
SI2135873T1 (sl) 2012-03-30
GB0403744D0 (en) 2004-03-24
WO2005080403A3 (en) 2005-11-24
US20080161565A1 (en) 2008-07-03
SG153856A1 (en) 2009-07-29
PT2135873E (pt) 2012-01-16
CY1112555T1 (el) 2016-02-10
US7626020B2 (en) 2009-12-01
EP2135873B1 (en) 2011-11-30
WO2005080403A2 (en) 2005-09-01
BRPI0507847A (pt) 2007-07-10
UA83418C2 (uk) 2008-07-10
CA2555554A1 (en) 2005-09-01
KR20120036998A (ko) 2012-04-18
AU2005214138A1 (en) 2005-09-01
IL177505A0 (en) 2006-12-10
UY28754A1 (es) 2005-09-30
KR20060129483A (ko) 2006-12-15
EP2135873A3 (en) 2010-03-24
PL2135873T3 (pl) 2012-03-30
IL194709A (en) 2010-12-30
JP2012031174A (ja) 2012-02-16
NO20064012L (no) 2006-11-06
TW200538451A (en) 2005-12-01
KR101196111B1 (ko) 2012-10-30
RU2386636C2 (ru) 2010-04-20
EP1718655A2 (en) 2006-11-08
CN1922193A (zh) 2007-02-28
CL2011003138A1 (es) 2012-06-22
CN1922193B (zh) 2012-12-26
ES2375201T3 (es) 2012-02-27
SA05260017B1 (ar) 2008-07-14
AR047810A1 (es) 2006-02-22
US20100094010A1 (en) 2010-04-15
ATE535532T1 (de) 2011-12-15
HRP20120031T1 (hr) 2012-02-29
ZA200606579B (en) 2008-01-30
JP2007523906A (ja) 2007-08-23
AU2005214138B2 (en) 2009-02-12
HK1139689A1 (en) 2010-09-24
RU2006133455A (ru) 2008-03-27
EP2325189A2 (en) 2011-05-25
IL177505A (en) 2010-12-30
MY142268A (en) 2010-11-15
DK2135873T3 (da) 2012-02-13
RS52300B (en) 2012-12-31
EP2325189A3 (en) 2011-10-26
EP2135873A2 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
TWI347947B (en) Process for preparing [4-(1,3,4-oxadiazol-2-yl)phenyl] boronic acid and use thereof
IL175550A0 (en) Heterocyclic boronic acid compounds
IL158756A0 (en) Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as anti-bacterial agents
HK1202254A1 (zh) -噁二唑苯甲酸化合物
ZA200804030B (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)benzamides and the salts thereof
IL190227A (en) Phenyl derivatives - [1,2,4] - oxadiazole - 5 - On with a phenyl group, their use in medicine, pharmaceuticals containing them, and a process for preparing the pharmaceutical preparations
IL183568A (en) Process for making 7,8-dihydro-5 h-patridine-6-onh
HK1081945A1 (en) Process for the synthesis of 4,5-dimethoxy-1-(methylaminomethyl)-benzocy clobutane, and the use thereof
IL191926A0 (en) Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof
ZA200702382B (en) Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines
IL176913A0 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
IL176916A0 (en) Aryl substituted heterocycles, method for production and use thereof as medicaments
ZA200704535B (en) Process for preparing rosuvastatin
PL1755596T3 (pl) Proces do wytwarzania wodorosiarczanu atazanawiru oraz nowe formy
IL188861A0 (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
ZA200700397B (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same
ZA200706248B (en) Novel heterocyclic oxime derivatives, method for preparing same and use thereof as hypoglycaemic or hypolipidemic agents
HK1123551A1 (en) Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl) amino benzonitrile
IL199239A0 (en) Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-
IL182445A0 (en) Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4difluoromethoxy-8-methanesulfona mido-dibenzo[b,d]furan-1-caboxamide
ZA200702070B (en) Process for preparing substituted 8-azablcyclo[3.2.1] octan-3-ols
IL182125A0 (en) Optically active 4,4-di-substituted oxazolidine derivatives and processes for the preparation thereof
PL378059A1 (pl) Optycznie czynne pochodne bisoksazoliny, sposób ich wytwarzania i zastosowania
IL163750A0 (en) Process for preparing (2-(4-(6-fluorobenzo(D)isoxazol-3-yl)-piperidin-1yl)-ethyl)-2- methyl-6,7,8,9-tetrahydro-4H-pyrido-(1,
AU2004905892A0 (en) Salts and process for preparing same

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees